Brash Biotech CEO Gets Comeuppance
Martin Shkreli, the hip-hop-loving, short-selling, drug-price-inflating, 32-year-old biotech chief executive, seemed to be daring the world to come after him. The world, or at least the U.S. Department of Justice, has now obliged.
To continue reading this article you must be a Bloomberg Professional Service Subscriber.
If you believe that you may have received this message in error please let us know.